Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lyra Therapeutics Inc LYRA

Healthcare
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that... see more

Recent & Breaking News (NDAQ:LYRA)

Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference

Business Wire November 12, 2020

Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire November 10, 2020

Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors

Business Wire October 28, 2020

Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210's Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis

GlobeNewswire September 10, 2020

Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis

GlobeNewswire September 3, 2020

Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 5, 2020

Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference

GlobeNewswire August 4, 2020

Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs

GlobeNewswire August 4, 2020

Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference

GlobeNewswire July 30, 2020

Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire July 24, 2020

Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development

GlobeNewswire July 7, 2020

Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index

GlobeNewswire June 25, 2020

Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 28, 2020

Lyra Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

Business Wire May 28, 2020

Lyra Therapeutics to Present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference

Business Wire May 8, 2020

Lyra Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Business Wire May 5, 2020

Lyra Therapeutics Announces Pricing of Initial Public Offering

Business Wire April 30, 2020